10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study.
OBJECTIVE
We determine the efficacy of conventional dose, external beam radiation for localized prostate cancer using cohort analysis with maximized followup.


METHODS
A total of 205 men with T1-2 prostate cancer were treated with conventional external beam radiation to a median and modal dose of 68.4 Gy during a 16-month period from 1991 to 1993. Followup was maximized in these patients, and median followup for those alive with or without disease was 114 months.


RESULTS
Median patient age at treatment was 72 years, and overall survival at 5 and 10 years was 78% and 53%, respectively. The actuarial risk of local failure was 18% at 10 years as was the risk of metastatic disease. The actuarial risk of being free of biochemical failure at 10 years (American Society for Therapeutic Radiology and Oncology definition) was 49%. That risk was 42% if the definition was used without backdating failure to a time between last low value and first increase. When a crude analysis of 10-year outcome was performed 127 of the 205 treated patients (62%) were still alive, including 59% with no evidence of biochemical failure and a median prostate specific antigen of 1.0 ng/ml. Of the 78 men (38% of total) who died during the 10 years 32 died either of or with recurrent cancer.


CONCLUSIONS
Mature followup minimizes many of the biases seen in previously published radiation series. This study provides a yardstick against which newer radiation modalities may be measured.
Zietman
A L
AL
Department of Radiation Oncology, Massachusetts General Hospital, Harvard medical School, Boston, USA. azeitman@partners.org
Chung
C S
CS
Coen
J J
JJ
Shipley
W U
WU
D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D015996:Survival Rate; D013997:Time Factors